Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Adam E. Singer
Patient Reported Outcomes and Quality of Life Considerations
Opinion|Videos|May 11, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment examines patient-reported outcomes and quality of life in the LITESPARK-011 trial. The findings indicate that overall quality of life was similar between the combination therapy and cabozantinib, despite differences in toxicity profiles. The discussion highlights that while the combination improves disease control, it does not clearly enhance patient-reported outcomes compared with single-agent therapy.
Safety Profile and Treatment Emergent Adverse Events
Opinion|Videos|May 4, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment reviews the safety and tolerability of belzutifan plus lenvatinib. The combination was associated with a high incidence of treatment-emergent adverse events, including grade 3 or higher toxicities, consistent with the known profiles of the individual agents.
Balancing Efficacy and Tolerability With TKIs in Advanced Renal Cell Carcinoma
In this segment on advanced renal cell carcinoma, Dr. Ornstein asks how clinicians differentiate among VEGF receptor targeted therapies when selecting treatment for patients with slower disease progression after prior immunotherapy. He highlights the perception that different TKIs may vary in both efficacy and toxicity. Dr. Friedlander explains that while these agents share similar mechanisms, subtle differences in target profiles contribute to variations in tolerability and clinical outcomes.
Interpreting Duration of Response in the Second Line Setting
Opinion|Videos|May 4, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment examines overall survival and duration of response outcomes in LITESPARK-011. While overall survival did not reach statistical significance at the time of analysis, numerical trends favored the combination therapy. The discussion highlights that survival data remain immature and may evolve with longer follow-up.
Second-Line Strategy After IO and TKI in Advanced Renal Cell Carcinoma
In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a patient who progresses after frontline immunotherapy plus VEGF receptor targeted therapy, with prior tolerability challenges including hand-foot syndrome and diarrhea. He highlights the expanding range of second-line options, including HIF-2α inhibitors. Dr. Singer discusses his approach, emphasizing that treatment selection depends on both disease tempo and prior toxicity.
Understanding Treatment Effect Timing
Opinion|Videos|April 27, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment focuses on interpreting the timing of treatment effects observed in progression-free survival curves. The discussion highlights that early outcomes appear similar between treatment arms, with separation occurring later in the follow-up period. This suggests that the benefit of the combination therapy may emerge over time rather than immediately.
Managing Toxicities of Bispecific Antibodies in Multiple Myeloma
Opinion|Videos|April 22, 2026 Author(s)Luciano Costa, MD , Muhamed Baljevic, MD, Carol Ann Huff, MD In this segment on early relapse multiple myeloma, Luciano Costa expands the discussion on safety by focusing on practical strategies to mitigate the characteristic toxicities associated with BCMA-directed bispecific antibodies. Inviting input from Carol Ann Huff, he highlights that adverse events such as cytokine release syndrome and infections remain a central topic of clinical discussion.
Interpreting Study Population and Applicability to Practice
Opinion|Videos|April 20, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment examines the baseline characteristics of patients enrolled in LITESPARK-011 and their relevance to clinical practice. The study population was well balanced between treatment arms, with similar distributions of age, performance status, and IMDC risk categories.
Second-Line Utilization and Evolving Options in Advanced Renal Cell Carcinoma
In this segment on advanced renal cell carcinoma, Dr. Ornstein explores real-world transition rates from first-line to subsequent lines of therapy, asking how often patients reach second- and third-line treatment in clinical practice. Dr. Friedlander highlights that real-world data suggest nearly half of patients may not receive second-line therapy, particularly outside academic settings, where patients may be older, more frail, or experience rapid disease progression.
LITESPARK-011 Trial Design and Endpoints
Opinion|Videos|April 13, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment reviews the design and statistical framework of the LITESPARK-011 trial. The study used dual primary endpoints of progression-free survival (PFS) and overall survival (OS), with a predefined allocation of type I error across endpoints to control statistical significance.
Treatment Intensity Tradeoffs and the Role of TKI Strategy
Opinion|Videos|April 6, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This segment transitions to the rationale for studying new treatment strategies in the post–PD-(L)1 setting, focusing on the lack of a clear standard of care after progression on immunotherapy. The discussion highlights that existing targeted therapies were largely developed before immune checkpoint inhibitors became widely used, leaving a gap in evidence for patients treated with modern regimens.
Framing LITESPARK-011 in a Changing RCC Landscape
Opinion|Videos|March 31, 2026 Author(s)Martin H. Voss, MD, Matthew T. Campbell, MD, MS This opening segment introduces the Between the Lines discussion of the phase 3 LITESPARK-011 study in advanced clear cell renal cell carcinoma (RCC). Drs. Martin Voss and Matthew Campbell outline the program’s focus on interpreting clinical data in the context of real-world decision-making.
Defining Early Relapse and Treatment Selection in Multiple Myeloma
Opinion|Videos|March 31, 2026 Author(s)Luciano Costa, MD , Muhamed Baljevic, MD, Carol Ann Huff, MD In this opening segment on early relapse multiple myeloma, Luciano Costa frames the evolving treatment landscape, highlighting how frontline quadruplet regimens and maintenance strategies have shifted expectations around remission duration and disease biology.
Symptom Trends in the Last Year of Life From 1998 to 2010: A Cohort StudySymptom Trends in the Last Year of Life
From Pardee RAND Graduate School, RAND Corporation, Santa Monica, California; University of Southern California, Los Angeles, California; David Geffen School of Medicine, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; Brown University, Providence, Rhode Island; Altarum Institute, Washington, DC; and Hospice and Palliative Nurses Association, Pittsburgh, Pennsylvania.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Adam E.
Contact Adam E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack